Company Overview of Iconic Therapeutics, Inc.
Iconic Therapeutics, Inc., a biopharmaceutical company, develops production and purification procedures for proteins that attack and destroy pathologic cells. It develops hI-con1, a recombinant protein that triggers immune cell-mediated killing of TF-expressing uterine serous papillary adenocarcinoma and clear cell ovarian cancer cells. The company was incorporated in 2002 and is based in Atlanta, Georgia.
127 Peachtree Street, N.E.
Atlanta, GA 30303
Founded in 2002
Key Executives for Iconic Therapeutics, Inc.
Chief Scientist and Scientific Advisor
Compensation as of Fiscal Year 2014.
Iconic Therapeutics, Inc. Key Developments
Iconic Therapeutics, Inc. Announces Management Appointments
Apr 16 14
Iconic Therapeutics, Inc. announced that MPM partner William Greene, MD, has joined the company as Chief Executive Officer. Additionally, MPM Managing Director Todd Foley, H.I.G. Managing Director Bruce Robertson, PhD, and Lundbeckfond Ventures Senior Partner Johan Kordel, PhD, have joined the Board of Directors. Prior to joining Iconic Therapeutics, Dr. Greene was a Managing Director at MPM Capital. Previously, he was a Senior Clinical Scientist at Genentech where he led the early clinical development of Lucentis for AMD.
Iconic Therapeutics, Inc. Announces Phase 1 Wet AMD Study Results
Nov 8 12
Iconic Therapeutics, Inc. announced that Dr. Christine Gonzales will present the results of its recently completed Phase 1 study of hI-con1 in wet adult macular degeneration (wet AMD) patients at the American Academy of Ophthalmology Retina Subspecialty Day on November 10, 2012 in Chicago. The purpose of the Phase 1 study was to evaluate the safety and tolerability of hI-con1 in wet AMD patients. The prospective, multi-center clinical study evaluated the safety and tolerability of a single, intravitreal injection of three different doses of hI-con1 in a total of 18 patients. hI-con1 was very well tolerated by all patients: no ocular or systemic safety signals were observed at any dose. A single injection of hI-con1 produced no dose limiting toxicities when used alone or when used with bevacizumab or ranibizumab. Notably, there were clear indications of dose-related, biologic activity in a number of patients, as indicated by increased visual acuity, reduced retinal thickness and CNV regression. Evidence of hI-con1 biological activity was observed both in previously untreated patients as well as patients not previously responding well to bevacizumab or ranibizumab (so-called sub-responders).
Similar Private Companies By Industry
Recent Private Companies Transactions
April 14, 2014
Most Searched Private Companies
Sponsored Financial Commentaries